Bayer's quest to revamp its drug discovery engine continues apace, with the company's recently acquired Vividion subsidiary forging an alliance with Tavros Therapeutics, aimed at finding new drug ...

Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.